- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05864599
External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group (EVALUATION)
Study Overview
Status
Conditions
Detailed Description
This study is intended as an independent validation series for previous studies performed in several European centers with less statistical power. We expect to validate the results from a previous study, reaching the sensitivity and specificity data obtained at generation and first external validation papers. The overall goal of this study is to perform a bigger external multicenter validation study to evaluate the sensitivity, specificity, NPV and PPV of Uromonitor for the detection of bladder cancer recurrence in an independent series of patients.
The specific objectives of this study protocol are the following:
Main endpoint:
• To evaluate the clinical sensitivity, specificity, NPV and PPV of Uromonitor in the detection of bladder cancer recurrence in patients previously diagnosed (over the last 3 months to 2 years) of NMIBC, treated or not, by testing a total of 600 patients (EVALUATION-CUETO Study)
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Carlos Lopez Borgonoz, Bsc
- Phone Number: 629329708
- Email: clopez@pharmalink.es
Study Locations
-
-
-
Valencia, Spain, 46015
- Hospital Vithas 9 d'Octubre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Main Outcome:
- Age >22.
- Patients with a history of non-muscle invasive bladder cancer (any risk group, any intravesical adjuvant treatment received) over the last 3 months to 2 years, initial or recurrent, undergoing regular cystoscopic surveillance. The criteria for cystoscope FU schedule has been already described in Methods following EAU 2022 Guidelines´ recommendations and related to initial NMIBC risk grouping.
- Patient must be able to provide at least 10 ml of urine.
- Additional 10 ml of urine needs to be collected for cytology.
Patients must be able to provide informed consent
2.- Subgroup analysis (secondary Objective 1):
- Age >22
- Patients with a history of primary non-muscle invasive bladder cancer with presence of CIS over the last 3 months to 3 years, and previously treated with BCG undergoing regular cystoscopic surveillance.
- Patient must be able to provide at least 10 ml of urine.
- Additional 10 ml of urine needs to be collected for cytology.
Patients must be able to provide informed consent.
3.- Subgroup analysis (secondary Objective 2):
- Age >22
- Patients included in both previous groups, having a positive Uromonitor® test and a negative cystoscopy to be followed by two years as previously described depending on initial NMIBC risk group. The rest of the patients will also be followed 2 years to detect later recurrences/progression figures.
Exclusion Criteria:
Patients who are unable to provide the minimum amount of urine needed to perform one test.
- Patients planning to undergo radical cystectomy or chemotherapy, radiation for UC
- Patients at risk for non-definitive information derived from the cystoscope due to different conditions:
- Not possible to ascertain informative cystoscope due to intolerance to the procedure
- Presence of bladder stone
- Presence of entero-vesical fistulae
- Presence of vesico-vaginal fistulae
- Non informative cystoscope due to macroscopic haematuria or cloudy urine
- Other conditions avoiding a clear tumour rule-out cystoscope
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity, specificity, NPV and PPV of Uromonitor
Time Frame: 2 years after diagnosis
|
To evaluate the clinical sensitivity, specificity, NPV and PPV of Uromonitor in the detection of bladder cancer recurrence in patients previously diagnosed (over the last 3 months to 2 years) of NMIBC, treated or not
|
2 years after diagnosis
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Statistics in CIS, treated or not
Time Frame: 2 years after diagnosis
|
To evaluate the clinical sensitivity and specificity of Uromonitor in the detection of bladder cancer recurrence in patients previously diagnosed (over the last 3 months to 3 years) of NMIBC with carcinoma in situ (CIS) associated and treated with BCG
|
2 years after diagnosis
|
Early diagnostics
Time Frame: 4 years after diagnosis
|
To check if Uromonitor can provide some early diagnostics of NIMBC by following for two years a group of false positive patients of both previous groups (Uromonitor Positive / Cystoscopy Negative)
|
4 years after diagnosis
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: José Rubio-Briones, MD PhD, Hospital 9 d'Octubre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
Other Study ID Numbers
- PIEM-AEU-2023-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-muscle-invasive Bladder Cancer
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Huazhong University of Science and TechnologyRecruitingBladder Cancer | Non-Muscle-Invasive Bladder CancerChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
-
RenJi HospitalBeiGene; RemeGen Co., Ltd.RecruitingHER2 | Non-Muscle Invasive Bladder CancerChina
-
White River Junction Veterans Affairs Medical CenterMedical University of South Carolina; National Cancer Institute (NCI); University...RecruitingNon-muscle-invasive Bladder CancerUnited States
-
Al-Azhar UniversityRecruiting
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Recruiting